The global CIS insulin market size is estimated to register a considerable CAGR during the forecast period, 2021-2028. The growth of the market is attributed to the increasing prevalence of diabetes across the globe due to changing lifestyle of people.
A peptide hormone produced by the pancreas is one of the key hormones for the human body. It helps the regulation of glucose into the blood cells and regulates the metabolism of fats and carbohydrates. When insulin is not produced in a sufficient amount in the body, it leads to sugar accumulation in the blood that results in diabetes. Diabetes is treated by providing insulin externally to the patient. As per the estimation by the International Diabetes Federation, the number of diabetic patients is expected to grow from 366 million in 2011 to 552 million in 2030. The report also stated that in 2013 approximately 382 million individuals were diagnosed with diabetes. Hence the rapid increase in the number of diabetic patients is expected to drive the market expansion.
There are about 100 million individuals around the world who need insulin. This also includes the number of patients who are suffering from type I and type II diabetes. Insulin has been used for the treatment of diabetes for over 90 years; however, still many people in need across several parts of regions are unable to afford and access it. In order to prevent complications, type I diabetic patients are treated with insulin to maintain the sugar level in their blood along with taking care of their lifestyle and diet.
The report on the global CIS insulin market includes an assessment of the market, trends, and segments. Overview and dynamics have also been included in the report.
Attributes |
Details |
Report Title |
CIS Insulin Market – Global Industry Analysis, Growth, Share, Size, Trends, And Forecast |
Base Year |
2020 |
Historic Data |
2018–2019 |
Forecast Period |
2021–2028 |
Segmentation |
Products (Intermediate Insulin, Rapid Acting Analog, Short Acting Insulin, Premixed Analog, Premixed Insulin, and Long-acting Analog), Sources (Analogs and Human Recombinant Insulin), and Applications (Type I Diabetes and Type II Diabetes) |
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
Key Players Covered in the Report |
Boehringer Ingelheim; Novo Nordisk; Sanofi Aventis; Takeda Pharmaceuticals; Nanjing Xinbai Pharmaceutical Co. Ltd.; Merck & Co. Inc.; Oramed Pharmaceuticals; Eli Lilly and Co.; and Biocon |
On the basis of products, the global CIS insulin market is divided into intermediate insulin, rapid acting analog, short acting insulin, premixed analog, premixed insulin, and long-acting analog. The long-acting analog segment held a large revenue share of the market in 2019 and is anticipated to dominate the market during the forecast period owing to its high cost.
Based on sources, the market is bifurcated into analogs and human recombinant insulin. Several insulin products are derived from various sources. The analogs segment is expected to account for a major revenue share of the market during the projected period owing to the penetration of various new products deep in the market.
On the basis of applications, the global CIS insulin market is bifurcated into type I diabetes and type II diabetes. The type I diabetes segment is estimated to exhibit high revenue growth of the market in the coming years owing to the increasing use of insulin for the treatment of type I diabetes along with the introduction of various new products in the market.
In terms of regions, the global CIS insulin market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. Europe is expected to dominate the market during the forecast period in terms of revenue attributed to subsidies provided by different governments in the region so that the medicines are easily accessible and affordable to common people. The further acceleration of the regional market growth is attributed to the well-establishment of healthcare service systems provided by the governments and wide funding for the development of biosimilar products.
The global CIS insulin market has been segmented on the basis of
Key players competing in the global CIS insulin market are Boehringer Ingelheim; Novo Nordisk; Sanofi Aventis; Takeda Pharmaceuticals; Nanjing Xinbai Pharmaceutical Co. Ltd.; Merck & Co. Inc.; Oramed Pharmaceuticals; Eli Lilly and Co.; and Biocon. Many of these players have adopted business strategies such as development of novel drugs, launch of new products, advancement of technologies, partnerships, mergers, and production capacity expansion in order to increase their expansion, their consumer base, and market position globally.
The global CIS insulin market has been segmented on the basis of
Key players competing in the global CIS insulin market are Boehringer Ingelheim; Novo Nordisk; Sanofi Aventis; Takeda Pharmaceuticals; Nanjing Xinbai Pharmaceutical Co. Ltd.; Merck & Co. Inc.; Oramed Pharmaceuticals; Eli Lilly and Co.; and Biocon. Many of these players have adopted business strategies such as development of novel drugs, launch of new products, advancement of technologies, partnerships, mergers, and production capacity expansion in order to increase their expansion, their consumer base, and market position globally.
Some other reports from this category!